1. Paiva B, San-Miguel J, Avet-Loiseau H. MRD in multiple myeloma: does CR really matter? Blood. 2022;140(23):2423-2428. 2. Oliva S, Bruinink DHO, Rihova L, et al. Minimal residual disease assessment by multiparameter flow c...
Bruno Paiva, Jesus F San-Miguel, Hervé Avet-Loiseau.MRD in multiple myeloma: does CR really matter? Blood (2022) 140 (23): 2423–2428. https://doi.org/10.1182/blood.2022016170
The increasing percentage of patients achieving deep responses in multiple myeloma (MM) has led to the need for more sophisticated instruments to measure residual disease as a potential source of relapse. Since minimal residual disease (MRD) assessment is mostly performed on a bone marrow specimen ...
参考文献 Szalat R, Anderson K, Munshi N. Role of minimal residual disease assessment in multiple myeloma. Haematologica; https://doi.org/10.3324/haematol.2023.284662 文章来源:聊聊血液
1. Soh KT, Wallace PK. Evaluation of measurable residual disease in multiple myeloma bymultiparametric flow cytometry: Current paradigm, guidelines, and future applications. Int JLab Hematol. 2021 Jul;43 Suppl 1:43-53. doi: 10.1111/ijlh.13562. PMID: 34288449. ...
美国时间4月12日,FDA ODAC会议上通过了一项将微小残留病(minimal residual disease,MRD)作为多发性骨髓瘤(multiple myeloma, MM)的加速批准终点的议题。 图1 会议主要讨论内容 PART 01 MM患者MRD检测的临床意义 多发性骨髓瘤MM是一种克隆浆细胞异常增殖的血液系统恶性疾病,多发于老年人,目前仍无法治愈。 在MM治疗过...
November 29th 2024 FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL December 14th 2024 The OncFive: Top Oncology Articles for the Week of 12/18 October 31st 2024 Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek...
MRD is a measure of how deep a remission you can achieve in a patient with multiple myeloma. There are 2 primary assays that are used to assess this: one is flow cytometry, where you’re looking with various markers on plasma cells to see how many residual cells there are at the end ...
这将增加根据MRD缓解进行患者分层的准确性,以及比较治疗组之间和临床试验之间的MRD阴性率的准确性。 参考文献 Bruno Paiva, Jesus F San-Miguel, Hervé Avet-Loiseau.MRD in multiple myeloma: does CR really matter? Blood (2022) 140 (23): 2423–2428. https://doi.org/10.1182/blood.2022016170...
Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Ioannis V Kostopoulos, et al. Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study. 2024 ASH. Abstract 361. ...